|
1
|
Cole BF, Logan RF, Halabi S, Benamouzig R,
Sandler RS, Grainge MJ, Chaussade S and Baron JA: Aspirin for the
chemoprevention of colorectal adenomas: meta-analysis of the
randomized trials. J Natl Cancer Inst. 101:256–266. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Martin C, Connelly A, Keku TO, Mountcastle
SB, Galanko J, Woosley JT, Schliebe B, Lund PK and Sandler RS:
Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal
adenomas. Gastroenterology. 123:1770–1777. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng J, Imanishi H, Amuro Y and Hada T:
NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell
growth and induced cell cycle arrest in human hepatocellular
carcinoma cell lines. Int J Cancer. 99:755–761. 2002. View Article : Google Scholar
|
|
4
|
Shureiqi I, Xu X, Chen D, Lotan R, Morris
JS, Fischer SM and Lippman SM: Nonsteroidal anti-inflammatory drugs
induce apoptosis in esophageal cancer cells by restoring
15-lipoxygenase-1 expression. Cancer Res. 61:4879–4884.
2001.PubMed/NCBI
|
|
5
|
Tang C, Wang C and Tang L: Effects of
combined octreotide and aspirin on the growth of gastric cancer.
Chin Med J (Engl). 116:373–377. 2003.PubMed/NCBI
|
|
6
|
Molina MA, Sitja-Arnau M, Lemoine MG,
Frazier ML and Sinicrope FA: Increased cyclooxygenase-2 expression
in human pancreatic carcinomas and cell lines: growth inhibition by
nonsteroidal anti-inflammatory drugs. Cancer Res. 59:4356–4362.
1999.
|
|
7
|
Baron JA, Cole BF, Sandler RS, Haile RW,
Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R,
Burke CA, et al: A randomized trial of aspirin to prevent
colorectal adenomas. N Engl J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y, Eu W, Seow-Choen F and Cheah Y:
Differential cytostatic effect of sodium salicylate in human
colorectal cancers using an individualized histoculture system.
Cancer Chemother Pharmacol. 49:473–478. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boudreau MD, Sohn KH, Rhee SH, Lee SW,
Hunt JD and Hwang DH: Suppression of tumor cell growth both in nude
mice and in culture by n-3 polyunsaturated fatty acids: mediation
through cyclooxygenase-independent pathways. Cancer Res.
61:1386–1391. 2001.
|
|
10
|
Elder DJ, Halton DE, Crew TE and Paraskeva
C: Apoptosis induction and cyclooxygenase-2 regulation in human
colorectal adenoma and carcinoma cell lines by the
cyclooxygenase-2-selective non-steroidal anti-inflammatory drug
NS-398. Int J Cancer. 86:553–560. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lönnroth C, Andersson M and Lundholm K:
Indomethacin and telomerase activity in tumor growth retardation.
Int J Oncol. 18:929–937. 2001.PubMed/NCBI
|
|
12
|
Yamamoto Y, Yin MJ, Lin KM and Gaynor RB:
Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem.
274:27307–27314. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rice PL, Washington M, Schleman S, Beard
KS, Driggers LJ and Ahnen DJ: Sulindac sulfide inhibits epidermal
growth factor-induced phosphorylation of extracellular-regulated
kinase 1/2 and Bad in human colon cancer cells. Cancer Res.
63:616–620. 2003.
|
|
14
|
Chung YM, Bae YS and Lee SY: Molecular
ordering of ROS production, mitochondrial changes, and caspase
activation during sodium salicylate-induced apoptosis. Free Radic
Biol Med. 34:434–442. 2003. View Article : Google Scholar
|
|
15
|
Cheng YL, Zhang GY, Xiao ZQ and Tang FQ:
Two-dimensional polyacrylamide gel electrophoresis analysis of
indomethacin-treated human colon cancer cells. World J
Gastroenterol. 11:2420–2425. 2005. View Article : Google Scholar
|
|
16
|
Corbett JM, Dunn MJ, Posch A and Görg A:
Positional reproducibility of protein spots in two-dimensional
polyacrylamide gel electrophoresis using immobilised pH gradient
isoelectric focusing in the first dimension: an interlaboratory
comparison. Electrophoresis. 15:1205–1211. 1994. View Article : Google Scholar
|
|
17
|
Haberkorn U, Altmann A and Eisenhut M:
Functional genomics and proteomics - the role of nuclear medicine.
Eur J Nucl Med Mol Imaging. 29:115–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pennica D, Swanson TA, Welsh JW, Roy MA,
Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, et al:
WISP genes are members of the connective tissue growth factor
family that are up-regulated in wnt-1-transformed cells and
aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA.
95:14717–14722. 1998. View Article : Google Scholar
|
|
19
|
Su F, Overholtzer M, Besser D and Levine
AJ: WISP-1 attenuates p53-mediated apoptosis in response to DNA
damage through activation of the Akt kinase. Genes Dev. 16:46–57.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Reed JC: Bcl-2 and the regulation of
programmed cell death. J Cell Biol. 124:1–6. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zha H, Aimé-Sempé C, Sato T and Reed JC:
Proapoptotic protein Bax heterodimerzies with Bcl-2 and with Bax
via a novel domain (BH3) distinct from BH1 and BH2. J Biol chem.
271:7440–7444. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yin XM, Oltvai ZN and Korsmeyer SJ: BH1
and BH2 domains of Bcl-2 are required for inhibition of apoptosis
and heterodimerization with Bax. Nature. 369:321–323. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang L, Yu J, Park BH, Kinzler KW and
Vogelstein B: Role of BAX in the apoptotic response to anticancer
agents. Science. 290:989–992. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Widmann C, Gibson S, Jarpe MB and Johnson
GL: Mitogen-activated protein kinase: conservation of a
three-kinase module from yeast to human. Physiol Rev. 79:143–180.
1999.PubMed/NCBI
|
|
25
|
Kyriakis JM and Avruch J: Mammalian
mitogen-activated protein kinase signal transduction pathways
activated by stress and inflammation. Physiol Rev. 81:807–869.
2001.PubMed/NCBI
|
|
26
|
Hayashi M, Fearns C, Eliceiri B, Yang Y
and Lee JD: Big mitogen-activated protein kinase 1/extracellular
signal-regulated kinase 5 signaling pathway is essential for
tumor-associated angiogenesis. Cancer Res. 65:7699–7706. 2005.
|
|
27
|
Hilger RA, Scheulen ME and Strumberg D:
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie.
25:511–518. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Denkert C, Koch I, Berger S, Köbel M,
Siegert A and Hauptmann S: Cytokine-suppressive anti-inflammatory
drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian
carcinoma cells. Cancer Lett. 195:101–109. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berger DH, Jardines LA, Chang H and
Ruggeri B: Activation of Raf-1 in human pancreatic adenocarcinoma.
J Surg Res. 69:199–204. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schwenger P, Alpert D, Skolnik EY and
Vilcek J: Cell-type-specific activation of c-Jun N-terminal kinase
by salicylates. J Cell Physiol. 179:109–114. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yip-Schneider MT and Schmidt CM: MEK
inhibition of pancreatic carcinoma cells by U0126 and its effect in
combination with sulindac. Pancreas. 27:337–344. 2003. View Article : Google Scholar : PubMed/NCBI
|
